One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation
-
Narrated by:
-
By:
About this listen
In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:
- The high incidence of lung cancer here in Manchester
- The differences between non-small cell and small-cell lung cancer
- Oncogenic drivers in lung cancer such as the KRAS mutation
- His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE
Colin Lindsay's research profile
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells
KRAS: Reasons for optimism in lung cancer
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Molecular characterization of primary and secondary resistance to RET inhibitors in patients
with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext